Molbio Diagnostics Ltd

Molbio Diagnostics Ltd has responded to stock exchange queries regarding a significant increase in its share trading volume. The company clarified that the volume movement is purely market-driven and that it has disclosed all material information as required by SEBI regulations. Molbio stated that there are no pending announcements or price-sensitive information that need to be disclosed to the exchanges.

Kotak Mahindra Mutual Fund (KMMF) has disclosed its acquisition of over 5.00% of the total equity share capital of Molbio Diagnostics Limited. The acquisition, made through various KMMF schemes via open market transactions, brings KMMF's total holding to 5.4834%. The disclosure was made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The total number of equity shares held by KMMF after the acquisition is 6,319,083 out of a total of 115,239,996 equity shares.

Kotak Mahindra Mutual Fund (KMMF) has acquired a significant stake in Molbio Diagnostics Limited, crossing the 5.00% threshold of the company's issued equity share capital. The acquisition was made through various KMMF schemes via open market purchases. Prior to this, KMMF held 4.9888% of Molbio Diagnostics' shares. After the acquisition, their total holding stands at 5.4834%. The total diluted share capital of Molbio Diagnostics before and after the acquisition remains 11,52,39,996 equity shares of Rs. 1.

Molbio Diagnostics Limited has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. India Business Excellence Fund III, a scheme of Business Excellence Trust III, has sold an aggregate of 30,00,000 equity shares of Molbio Diagnostics Limited on September 23, 2026. This sale resulted in a decrease in their shareholding from 11,52,39,996 shares to 11,22,39,996 shares. The transaction was conducted via open market sale. The computed percentage change in holding is not explicitly stated but can be inferred from the change in absolute numbers.

India Business Excellence Fund III has sold 23,77,627 equity shares of Molbio Diagnostics Limited, representing a 2.07% stake. The sale occurred on September 30, 2026. Prior to the transaction, the fund held 1,02,76,750 shares, amounting to 8.92% of the total equity. After the sale, their holding reduced to 78,99,123 shares, representing 6.85% of the total equity. This sale triggered the disclosure requirements under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, as the disposal breached the 2% threshold.

Molbio Diagnostics Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from October 01, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ended September 30, 2026. The specific date for the Board Meeting to consider these results will be communicated separately. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Molbio Diagnostics Ltd announced the re-appointment of M/s K. S. Kamalakara & Co. as the company's Cost Auditors for the Financial Year 2026-27. The decision was approved by the Board of Directors during a meeting held on September 25, 2026. The firm, a peer-reviewed entity with registration number 000296, specializes in various financial and accounting services including cost accounting and auditing. The disclosure regarding this re-appointment is in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the company has also made this information available on its website.

Molbio Diagnostics Ltd has received a revised disclosure from India Business Excellence Fund III regarding the sale of equity shares. The fund sold 30,00,000 equity shares, representing 2.60% of the total share capital, on September 23, 2026. This sale reduces their holding from 11.52% to 8.92%. The transaction was conducted via the open market. This revised disclosure supersedes a previous one due to a clerical error.

India Business Excellence Fund III, a scheme of Business Excellence Trust III, has sold an aggregate of 30,00,000 equity shares of Molbio Diagnostics Limited. The transaction, which occurred on September 23, 2026, resulted in the fund's holding decreasing from 11.52% to 11.22% of the total equity share capital. This sale triggered the disclosure requirements under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The sale was conducted via the open market.

India Business Excellence Fund III, a shareholder in Molbio Diagnostics Limited, has sold 30,00,000 equity shares, representing approximately 2.57% of the total capital. The sale occurred on September 23, 2026, and was conducted via open market transactions. Following the sale, the fund's holding in Molbio Diagnostics has reduced from 11,52,39,996 shares to 11,22,39,996 shares. This transaction triggered the disclosure requirements under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, as the disposal breached the 2% threshold.